+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Atrial Fibrillation Surgery Market (2021-2026) by Product, Procedure, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 168 Pages
  • May 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5397306
The Global Atrial Fibrillation Surgery Market is estimated to be USD 2. 13 Bn in 2021 and is expected to reach USD 4.36 Bn by 2026, growing at a CAGR of 15.4%.



Market Dynamics

The major factors driving the growth of the global atrial fibrillation surgery market are the rise in the number of people suffering from atrial fibrillation conditions as well as an increase in health concerns caused by obesity, diabetes, and high alcohol use. Furthermore, the Increased demand for catheter ablation for cardiac arrhythmia therapy, as well as an increase in the rates of CVD and atrial fibrillation, are expected to boost the market growth. In addition, the rapid improvement in technology, increase in the number of atrial fibrillation surgical and catheter ablation procedures, increase in the applications from emerging economies are anticipated to offer significant growth opportunities for the market.

However, a scarcity of qualified and educated staff, as well as adverse preferences for pharmaceutical medicines over AF treatment devices, is restraining the atrial fibrillation surgery market's growth. In addition, high recurrence and complication rates are expected to create challenges for market growth.

Market Segmentation

The Global Atrial Fibrillation Surgery Market is segmented further based on Product, Procedure, and Geography.

By Product, the market is classified into catheter ablation products and surgical ablation products. Amongst the two, the catheter ablation product segment is estimated to hold the highest market share during the forecast period.

By Procedure, the market is classified as catheter ablation procedures and surgical ablation procedures. Amongst the two, the catheter ablation procedures segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Tempus announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. - 24th March 2021
2. Medtronic received approval from Food and Drug Administration (FDA) for DiamondTemp Ablation (DTA) system, which treats patients with recurrent, symptomatic paroxysmal atrial fibrillation (AF) and who have been unresponsive to drug therapy.. - 29th January 2021

Company Profiles

Some of the companies covered in this report are Abbott Laboratories, Advansta, Inc, Atricure, Inc, Biotronik SE & CO. KG, Boehringer Ingelheim GmbH, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Atrial Fibrillation Surgery Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s positioning tool.

Report Highlights:
  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Atrial Fibrillation Surgery Market

What is the estimated value of the Global Atrial Fibrillation Surgery Market?

The Global Atrial Fibrillation Surgery Market was estimated to be valued at $2130 Million in 2021.

What is the growth rate of the Global Atrial Fibrillation Surgery Market?

The growth rate of the Global Atrial Fibrillation Surgery Market is 15.4%, with an estimated value of $4360 Million by 2026.

What is the forecasted size of the Global Atrial Fibrillation Surgery Market?

The Global Atrial Fibrillation Surgery Market is estimated to be worth $4360 Million by 2026.

Who are the key companies in the Global Atrial Fibrillation Surgery Market?

Key companies in the Global Atrial Fibrillation Surgery Market include Abbott Laboratories, Advansta, Inc, Atricure, Inc, BIOTRONIK SE & CO. KG, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol, Myers Squibb and Carima, Inc.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Surge in Cases of Atrial Fibrillation in Geriatric Population
4.1.2 Rising Number of Programs to Enhance Public Awareness
4.1.3 Government Initiatives in Healthcare Sector
4.2 Restraints
4.2.1 High Invest Cost
4.3 Opportunities
4.3.1 Rising Technological Advancement for Catheter Ablation
4.3.2 Growing Healthcare Sectors in Developing Countries
4.4 Challenges
4.4.1 Lack of Skilled Professionals
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Atrial Fibrillation Surgery Market, By Product
6.1 Introduction
6.2 Catheter Ablation Product
6.3 Surgical Ablation Product
7 Global Atrial Fibrillation Surgery Market, By Procedure
7.1 Introduction
7.2 Catheter Ablation Procedures
7.3 Surgical Ablation Procedures
8 Global Atrial Fibrillation Surgery Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 South America
8.3.1 Brazil
8.3.2 Argentina
8.3.3 Chile
8.3.4 Colombia
8.4 Europe
8.4.1 UK
8.4.2 France
8.4.3 Germany
8.4.4 Italy
8.4.5 Spain
8.4.6 Netherlands
8.4.7 Sweden
8.4.8 Russia
8.4.9 Rest of Europe
8.5 Asia-Pacific
8.5.1 China
8.5.2 Japan
8.5.3 India
8.5.4 Indonesia
8.5.5 Malaysia
8.5.6 South Korea
8.5.7 Australia
8.5.8 Sri Lanka
8.5.9 Thailand
8.5.10 Rest of APAC
8.6 Middle-East and Africa
8.6.1 Qatar
8.6.2 Saudi Arabia
8.6.3 South Africa
8.6.4 United Arab Emirates
9 Competitive Landscape
9.1 Competitive Quadrant
9.2 Market Share Analysis
9.3 Strategic Initiatives
9.3.1 M&A and Investments
9.3.2 Partnerships and Collaborations
9.3.3 Product Developments and Improvements
10 Company Profiles
10.1 Abbott Laboratories
10.2 Advansta, Inc
10.3 Atricure, Inc
10.4 BIOTRONIK SE & CO. KG
10.5 Boehringer Ingelheim GmbH
10.6 Boston Scientific Corporation
10.7 Bristol-Myers Squibb
10.8 Cardiofocus, Inc
10.9 Carima, Inc
10.10 Endo Photonix, Inc
10.11 Endoscopic Technologies Inc
10.12 GE Healthcare
10.13 Johnson & Johnson Services, Inc
10.14 Koninklijke Philips N.V
10.15 Medtronic PLC
10.16 MicroPort Scientific Corporation
10.17 Osypka AG
10.18 Sanofi S.A
10.19 Siemens Healthineers AG
10.20 St. Jude Medical, Inc
10.21 Tempus
11 Appendix
11.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Advansta, Inc
  • Atricure, Inc
  • BIOTRONIK SE & CO. KG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb
  • Cardiofocus, Inc
  • Carima, Inc
  • Endo Photonix, Inc
  • Endoscopic Technologies Inc
  • GE Healthcare
  • Johnson & Johnson Services, Inc
  • Koninklijke Philips N.V
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Osypka AG
  • Sanofi S.A
  • Siemens Healthineers AG
  • St. Jude Medical, Inc
  • Tempus